Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations

V.M. Meidan, J. Glezer, S. Salomon, Y. Sidi, Y. Barenholz, J.S. Cohen, G. Lilling

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. However, effective therapy requires efficient ODN delivery, which may be achieved by employing G3139 lipoplexes. Yet, lipofection is a complex, multifactorial process that is still poorly understood. In order to shed more light on this issue, we prepared 18 different G3139 lipoplex formulations and compared them in terms of their capability to transfect MCF-7 breast cancer cells. Each formulation was composed of a cationic lipid and sometimes a helper lipid. The cationic lipid was either DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), DC-CHOL (3β[N-(N',N'-dimethylaminoethane)carbamoyl]-cholesterol), or CCS (ceramide carbomoyl spermine). The helper lipid was either DOPC, DOPE, or cholesterol. Each lipid combination existed in two different structural forms - either large unilamellar vesicles (∼100 nm LUV) or unsized heterolamellar vesicles (UHV). Cell proliferation assays were used to evaluate the cytotoxicity of G3139 lipoplexes, control cationic lipid assemblies, and free G3139. Western blots were used to confirm the specific activity of G3139 as an anti-bcl-2 antisense agent. We determined that treatment of MCF-7 cells with G3139:CCS lipoplexes (UHV-derived) produced a maximal 50-fold improvement in antisense efficacy compared to treatment with free G3139. The other G3139 lipoplexes were not superior to free G3139. Thus, successful lipofection requires precise optimization of lipoplex lipid composition, structure, and concentration.
Original languageEnglish
Pages (from-to)27-43
Number of pages16
JournalJournal of Liposome Research
Volume16
Issue number1
DOIs
Publication statusPublished - 2006

Fingerprint

Breast Neoplasms
Lipids
Spermine
Ceramides
oblimersen
Unilamellar Liposomes
Antisense Oligonucleotides
MCF-7 Cells
Chlorides
Therapeutics
Down-Regulation
Western Blotting
Cholesterol
Cell Proliferation
Pharmaceutical Preparations

Keywords

  • G3139
  • antisense oligonucleotide
  • DOTAP
  • ceramide carbamoyl spermine
  • pharmacology

Cite this

Meidan, V.M. ; Glezer, J. ; Salomon, S. ; Sidi, Y. ; Barenholz, Y. ; Cohen, J.S. ; Lilling, G. / Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations. In: Journal of Liposome Research. 2006 ; Vol. 16, No. 1. pp. 27-43.
@article{b34f1f70b0744128a5ff64c7d96ca89c,
title = "Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations",
abstract = "G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. However, effective therapy requires efficient ODN delivery, which may be achieved by employing G3139 lipoplexes. Yet, lipofection is a complex, multifactorial process that is still poorly understood. In order to shed more light on this issue, we prepared 18 different G3139 lipoplex formulations and compared them in terms of their capability to transfect MCF-7 breast cancer cells. Each formulation was composed of a cationic lipid and sometimes a helper lipid. The cationic lipid was either DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), DC-CHOL (3β[N-(N',N'-dimethylaminoethane)carbamoyl]-cholesterol), or CCS (ceramide carbomoyl spermine). The helper lipid was either DOPC, DOPE, or cholesterol. Each lipid combination existed in two different structural forms - either large unilamellar vesicles (∼100 nm LUV) or unsized heterolamellar vesicles (UHV). Cell proliferation assays were used to evaluate the cytotoxicity of G3139 lipoplexes, control cationic lipid assemblies, and free G3139. Western blots were used to confirm the specific activity of G3139 as an anti-bcl-2 antisense agent. We determined that treatment of MCF-7 cells with G3139:CCS lipoplexes (UHV-derived) produced a maximal 50-fold improvement in antisense efficacy compared to treatment with free G3139. The other G3139 lipoplexes were not superior to free G3139. Thus, successful lipofection requires precise optimization of lipoplex lipid composition, structure, and concentration.",
keywords = "G3139, antisense oligonucleotide, DOTAP, ceramide carbamoyl spermine, pharmacology",
author = "V.M. Meidan and J. Glezer and S. Salomon and Y. Sidi and Y. Barenholz and J.S. Cohen and G. Lilling",
year = "2006",
doi = "10.1080/08982100500528685",
language = "English",
volume = "16",
pages = "27--43",
journal = "Journal of Liposome Research",
issn = "0898-2104",
number = "1",

}

Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations. / Meidan, V.M.; Glezer, J.; Salomon, S.; Sidi, Y.; Barenholz, Y.; Cohen, J.S.; Lilling, G.

In: Journal of Liposome Research, Vol. 16, No. 1, 2006, p. 27-43.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations

AU - Meidan, V.M.

AU - Glezer, J.

AU - Salomon, S.

AU - Sidi, Y.

AU - Barenholz, Y.

AU - Cohen, J.S.

AU - Lilling, G.

PY - 2006

Y1 - 2006

N2 - G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. However, effective therapy requires efficient ODN delivery, which may be achieved by employing G3139 lipoplexes. Yet, lipofection is a complex, multifactorial process that is still poorly understood. In order to shed more light on this issue, we prepared 18 different G3139 lipoplex formulations and compared them in terms of their capability to transfect MCF-7 breast cancer cells. Each formulation was composed of a cationic lipid and sometimes a helper lipid. The cationic lipid was either DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), DC-CHOL (3β[N-(N',N'-dimethylaminoethane)carbamoyl]-cholesterol), or CCS (ceramide carbomoyl spermine). The helper lipid was either DOPC, DOPE, or cholesterol. Each lipid combination existed in two different structural forms - either large unilamellar vesicles (∼100 nm LUV) or unsized heterolamellar vesicles (UHV). Cell proliferation assays were used to evaluate the cytotoxicity of G3139 lipoplexes, control cationic lipid assemblies, and free G3139. Western blots were used to confirm the specific activity of G3139 as an anti-bcl-2 antisense agent. We determined that treatment of MCF-7 cells with G3139:CCS lipoplexes (UHV-derived) produced a maximal 50-fold improvement in antisense efficacy compared to treatment with free G3139. The other G3139 lipoplexes were not superior to free G3139. Thus, successful lipofection requires precise optimization of lipoplex lipid composition, structure, and concentration.

AB - G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. However, effective therapy requires efficient ODN delivery, which may be achieved by employing G3139 lipoplexes. Yet, lipofection is a complex, multifactorial process that is still poorly understood. In order to shed more light on this issue, we prepared 18 different G3139 lipoplex formulations and compared them in terms of their capability to transfect MCF-7 breast cancer cells. Each formulation was composed of a cationic lipid and sometimes a helper lipid. The cationic lipid was either DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), DC-CHOL (3β[N-(N',N'-dimethylaminoethane)carbamoyl]-cholesterol), or CCS (ceramide carbomoyl spermine). The helper lipid was either DOPC, DOPE, or cholesterol. Each lipid combination existed in two different structural forms - either large unilamellar vesicles (∼100 nm LUV) or unsized heterolamellar vesicles (UHV). Cell proliferation assays were used to evaluate the cytotoxicity of G3139 lipoplexes, control cationic lipid assemblies, and free G3139. Western blots were used to confirm the specific activity of G3139 as an anti-bcl-2 antisense agent. We determined that treatment of MCF-7 cells with G3139:CCS lipoplexes (UHV-derived) produced a maximal 50-fold improvement in antisense efficacy compared to treatment with free G3139. The other G3139 lipoplexes were not superior to free G3139. Thus, successful lipofection requires precise optimization of lipoplex lipid composition, structure, and concentration.

KW - G3139

KW - antisense oligonucleotide

KW - DOTAP

KW - ceramide carbamoyl spermine

KW - pharmacology

UR - http://dx.doi.org/10.1080/08982100500528685

U2 - 10.1080/08982100500528685

DO - 10.1080/08982100500528685

M3 - Article

VL - 16

SP - 27

EP - 43

JO - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

IS - 1

ER -